Bibliografía y referencias

Los contenidos de MG Informa se basan en guías de práctica clínica internacionales, metaanálisis y revisiones sistemáticas publicadas en revistas de alto impacto. A continuación encontrará las referencias principales organizadas por relevancia temática.

Referencias principales

1. Ref. 1 · 2015
   Myasthenia gravis: subgroup classification and therapeutic strategies
   Gilhus NE, Verschuuren JJ.
   Lancet Neurol. 14(10):1023-1036
   Ver en PubMed
2. Ref. 2 · 2016
   International consensus guidance for management of myasthenia gravis
   Sanders DB, Wolfe GI, Benatar M, et al.
   Neurology. 87(4):419-425
   Ver en PubMed
3. Ref. 3 · 2016
   Randomized trial of thymectomy in myasthenia gravis
   Wolfe GI, Kaminski HJ, Aban IB, et al. (MGTX Study Group)
   N Engl J Med. 375(6):511-522
   Ver en PubMed
4. Ref. 4 · 2017
   Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis
   Howard JF Jr, Utsugisawa K, Benatar M, et al. (REGAIN Study Group)
   Lancet Neurol. 16(12):976-986
   Ver en PubMed
5. Ref. 5 · 2016
   Myasthenia gravis
   Gilhus NE.
   N Engl J Med. 375(26):2570-2581
   Ver en PubMed
6. Ref. 6 · 2023
   Guidelines of the American Academy of Neurology for the treatment of myasthenia gravis: immunosuppressive therapies
   Narayanaswami P, Sanders DB, Wolfe G, et al.
   Neurology. 100(14):671-683
   Ver en PubMed
7. Ref. 7 · 2023
   Long-term safety and efficacy of efgartigimod in patients with generalised myasthenia gravis
   Muppidi S, Utsugisawa K, Benatar M, et al. (CHAMPION MG Study Group)
   Lancet Neurol. 22(9):819-829
   Ver en PubMed
8. Ref. 8 · 2017
   Safety and efficacy of amifampridine phosphate in patients with congenital myasthenic syndrome (CMS)
   Bril V, Benatar M, Wolfe GI, et al. (ADAPT Study Group)
   Muscle Nerve. 55(6):848-854
   Ver en PubMed
9. Ref. 9 · 2012
   IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis
   Viegas S, Jacob S, Leite MI, et al.
   Brain. 135(Pt 6):1800-1812
   Ver en PubMed
10. Ref. 10 · 2003
    Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
    Evoli A, Tonali PA, Padua L, et al.
    Brain. 126(Pt 10):2304-2311
    Ver en PubMed
11. Ref. 11 · 2011
    Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts
    Guptill JT, Sanders DB, Evoli A.
    Muscle Nerve. 44(1):36-40
    Ver en PubMed
12. Ref. 12 · 2010
    Differential mechanisms of neuromuscular fatigue and weakness in Lambert-Eaton myasthenic syndrome
    Pasnoor M, Hejal R, Ayyar DR, et al.
    Muscle Nerve. 42(6):913-920
    Ver en PubMed
13. Ref. 13 · 2019
    Acetylcholinesterase inhibitors in myasthenia gravis. Current status and future directions
    Zuliani G, Franceschi M, Bordonali T, et al.
    Expert Opin Pharmacother. 20(13):1583-1592
    Ver en PubMed
14. Ref. 14 · 2016
    Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis
    Wolfe GI, Trivedi JR, Oh SJ, et al.
    N Engl J Med. 375(26):2570-2581
    Ver en PubMed
15. Ref. 15 · 2012
    Myasthenia gravis
    Silvestri NJ, Wolfe GI.
    Semin Neurol. 32(3):215-226
    Ver en PubMed

Cómo se cita este sitio

Si utiliza información de MG Informa con fines académicos o divulgativos, sugerimos la siguiente referencia: